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ABSTRACT
Background: The prevalence of patients with chronic rhinosinusitis (CRS) refractory to traditional therapy ap-
pears to be on the increase. In these cases, CRS tends to be associated with bronchial asthma (BA), espe-
cially, aspirin-intolerant asthma (AIA). On the other hand, arachidonic acid metabolites have been extensively
investigated in the pathogenesis of BA. We sought to assess the role of prostaglandin D2 (PGD2) and
prostaglandin E2 (PGE2) in the recalcitrant pathophysiology of CRS.
Methods: Samples were prepared from the nasal polyps and mucosa of 40 patients undergoing endoscopic
sinus surgery (ESS) at our hospital. The nasal polyp specimens obtained from the patients with CRS were di-
vided into three groups, as follows: the CRS-AIA group, consisting of specimens obtained from patients with
CRS complicated by AIA, the CRS-ATA group, consisting of specimens obtained from patients with CRS asso-
ciated with aspirin-tolerant asthma (ATA), and the CRS-NA group, consisting of specimens obtained from CRS
patients without BA. PGD2 and PGE2 were extracted from the specimens and quantified.
Results: The concentrations of PGD2 were significantly higher in the nasal polyps of the CRS-ATA group. The
concentrations of PGE2 were lowest in the nasal polyps of the CRS-AIA group. The PGD2PGE2 ratio was
highest in the CRS-AIA group.
Conclusions: It has previously been reported that CRS complicated by AIA is most likely to be characterized
by repeated remissions and relapses, and is thus the most intractable. We may therefore say that the PGD2
PGE2 ratio reflects the intractable nature of CRS.
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INTRODUCTION
Chronic rhinosinusitis (CRS) is an inflammatory con-
dition of the paranasal mucous membrane, character-
ized by the accumulation of eosinophils, fibroblasts,
mast cells and goblet cells.1-3 Nasal polyposis is fre-
quently associated with other conditions, such as
bronchial asthma (BA),4-6 including aspirin-intolerant
asthma (AIA).7 Recently, although there has been an
increase in the cure rates of patients with CRS, with
the institution of low-dose long-term treatment with
macrolide antibiotics and adoption of endoscopic si-
nus surgery (ESS),8,9 there still remains a substantial
number of patients with a poor prognosis.10 Such pa-
tients with a poor prognosis have been found to in-
clude a high proportion of patients with lower respira-
tory tract disorders, such as BA.
BA is a chronic inflammatory disorder character-
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Table 1 Patient clinical data
CRS-AIACRS-ATACRS-NAControl
712147N
2/53/92/121/6Sex (F/M)
48.43 ± 18.7543.75 ± 14.4244.14 ± 16.0832.43 ± 10.26Age average
26―7118―6520―7119―46Age range
206.86 ± 374.13257.91 ± 258.73100.25 ± 142.65101.71 ± 81.41 Total IgE
13.39 ± 9.88 8.33 ± 4.442.57 ± 1.263.78 ± 2.56Peripheral blood eosinophils (%)
ized by mast cell and eosinophilic infiltration of the
airways. BA can be categorized into two distinct types
according to the presence or absence of aspirin sensi-
tivity: aspirin-intolerant asthma (AIA) and aspirin-
tolerant asthma (ATA). In particular, AIA is a distinct
clinical syndrome affecting a significant proportion of
adult patients with BA, in whom aspirin and other
nonsteroidal anti-inflammatory drugs (NSAIDs) pre-
cipitate bronchoconstriction.11,12 Patients with AIA
often have a particularly severe form of BA, associ-
ated with rhinorrhea and recurrent polyp forma-
tion.11,12
Arachidonic acid metabolites have been exten-
sively investigated in the pathogenesis of BA. Cystei-
nyl leukotrienes (CysLTs), strong proinflammatory
factors generated from arachidonic acid through the
5-lipoxygenase pathway, have been recognized as the
key mediators of an asthmatic attack.13 CysLTs are
components of the slow-reacting substance of ana-
phylaxis (SRS-A) and have been shown to have pro-
found effects on the airways,14,15 e.g., able to induce
airway smooth muscle contraction and vasodilatation,
enhance vascular permeability, and alter the remodel-
ing process in asthma.16,17 Prostaglandin D2 (PGD2)
is a potent bronchoconstrictor and its effect is medi-
ated by the TP receptor.18 Therefore, PGD2 may be
an important mediator of airway smooth muscle con-
traction in an immediate asthmatic reaction.19 Fur-
thermore, it has recently been reported from experi-
ments using knockout mice that PGD2 exacerbates
asthma.20,21 In contrast, prostaglandin E2 (PGE2) pro-
tects airways against inflammation and promotes nor-
mal airway function.22,23 On the other hand, PGE2 en-
hances immunoglobulin (Ig) E production. PGE2 pro-
motes IL-4 production from Th2 cells, suppresses
IFN-γ production from Th1 cells, and promotes IgE
production from B cells.24
As described above, a large number of reports
have been published concerning the involvement of
arachidonic acid metabolites in the pathophysiology
of BA. It seems probable that arachidonic acid me-
tabolites are among the factors responsible for the in-
tractable course of CRS as well. Taking into account
this possibility, additionally there have been recent
reports that PGD2 and PGE2 are closely involved in
airway inflammation25-27 and that the balance be-
tween PGD2 and PGE2 production determines the se-
verity of inflammation in various inflammatory condi-
tions.28-30 Consequently, we undertook the present
study in which patients with CRS associated with BA
were divided according to whether they had ATA or
AIA, and the amounts of PGD2 and PGE2 in the nasal
polyps were compared between patients with intracta-
ble CRS complicated by ATA and those with CRS
complicated by AIA.
METHODS
SUBJECTS
Nasal polyp tissue specimens were obtained at the
time of surgery from subjects (n = 33) referred to
Jikei University Hospital for ESS. To examine the role
of the arachidonic acid metabolites in the pathogene-
sis of CRS, the specimens were obtained from CRS
patients classified into 3 subgroups, as follows: CRS
without BA (CRS-NA group; n = 14), CRS associated
with ATA (CRS-ATA group; n = 12), and CRS associ-
ated with AIA (CRS-AIA group; n = 7). In addition,
specimens from 7 controls were also examined (5
middle turbinate mucosa specimens obtained from
patients with non-allergic rhinitis and 2 middle mea-
tus mucosa specimen obtained from a blowout frac-
ture patient). Informed consent was obtained from all
of the patients prior to their enrollment in the study,
and the study was approved by the ethics committee
at the Jikei University Hospital. The clinical data of
the patients are summarized in Table 1. Before the
ESS, measurements of the serum IgE levels and pe-
ripheral blood eosinophil counts, as well as sinus
computed tomographic (CT) studies, were performed
for each patient.
CLINICAL ASSESSMENT
The diagnosis of CRS was based on the typical symp-
toms (nasal congestion, dysosmia, etc.) as assessed
from the documented medical history, the presence
of endoscopically visible nasal polyps arising from the
middle nasal meatus, and involvement of the ethmoi-
dal and maxillary sinuses as visualized in limited CT
scans of the paranasal sinuses.
The diagnosis of asthma was made at the Depart-
ment of Pulmonology, Jikei University Hospital,
based on the documented clinical history of the typi-
cal symptoms. The diagnosis of AIA was based on a
history of asthma exacerbation, nasal congestion, and
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Fig. 1 PGD2 (a), PGE2 (b) and CysLTs (c) concentrations in the nasal polyps. Between-group comparisons were performed 
by Mann-Whitney’ sU-test with Bonferoni corection ( ＊ p＜0.05).
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or rhinorrhea after the ingestion of aspirin or other
nonsteroidal anti-inflammatory drugs.
QUANTIFICATION OF ARACHIDONIC ACID ME-
TABOLITES
The nasal polyp tissue specimens were homogenized
in ethanol to extract the lipid fraction, the arachidonic
acid metabolites were stabilized, and the cellular pro-
tein was removed. After centrifugation of the precipi-
tated proteins, the supernatants were dried, resus-
pended in 80% ethanol and loaded on to a C18 Sep-
Pak column (Waters, Milford, MA). This column was
rinsed with ultra pure water followed by ethyl acetate,
and the arachidonic acid metabolites were then
eluted with ethanolwater (90 : 10). PGD2, PGE2 and
CysLTs were quantified using a high-sensitivity com-
petitive enzyme immunoassay kit (EIA kit; Cayman
Chemical, Ann Arbor, MI, USA), in accordance with
the manufacturer’s directions. The EIA is a competi-
tive sandwich enzyme-linked immunosorbent assay
technique, and the data were determined in compari-
son with standards for arachidonic acid metabolites.
Data were expressed as picograms of PGD2, PGE2
and CysLTs per gram of nasal polyp tissue in the
original homogenate.
IMMUNOHISTOCHEMICAL ANALYSIS
Monoclonal antibodies against human eosinophil cat-
ionic protein (EG2: Pharmacia, Uppsala, Sweden) and
mast cell tryptase (Chemicon International, Teme-
cula, CA, USA), CD68 (Dako Cytomation, Glostrup,
Denmark) were used for the immunohistochemical
analysis. Immunostaining with the avidin-biotin com-
plex was performed as described previously.31 In
brief, deparaffinized sections were initially incubated
with 3% H2O2 in methanol for 15 minutes to quench
the endogenous peroxidase activity, washed twice
with TBS (Dako Cytomation) and incubated over-
night at 4℃ with the primary antibody specific for
EG2, mast cell tryptase or CD68; they were then
washed and incubated for 30 minutes with Envision
APⓇ (Dako, Cambridgeshire, UK) or Envision+Ⓡ
(Dako). After being washed again with TBS, color de-
velopment was conducted using Fast Red (Sigma,
Poole, UK) or diaminobenzidine (DAB; Dako) as the
chromogen for signal visualization. Using this
method, the cells expressing tryptase or CD68 were
visualized in brown color (using DAB) while those
expressing EG2 were red in color (using Fast Red).
Negative controls were prepared by replacing the pri-
mary antibodies with isotype immunoglobulin.
Cells in the coded biopsy sections were counted by
an investigator blinded to the protocol. The cells
showing positive immunostaining in the nasal submu-
cosal region where the highest cellular infiltration
was seen were counted under a microscope. Then,
the average number of positive cells in three high-
power fields (200× or 400×) was determined.
STATISTICAL ANALYSIS
All the statistical analyses were nonparametric.
Between-group comparisons were performed by the
nonparametric Mann-Whitney’s U-test with Bonfer-
roni correction. Correlation analysis was performed
using Spearman’s rank correlation coefficient Differ-
ences (two-sided) were considered significant when
the P value was less than 0.05.
RESULTS
PGD2, PGE2 AND CysLTs CONCENTRATIONS IN
THE NASAL POLYPS
The concentrations of PGD2, PGE2 and CysLTs deter-
mined in the nasal polyps are summarized in Figure
1. The concentrations of PGD2 were significantly
higher in the nasal polyps of the CRS-ATA group as
compared with those in the control specimens (P =
0.035, Fig. 1a). The concentrations of PGD2 tended to
be higher in the nasal polyps of the CRS-ATA group
than in those of the CRS-AIA group, but this differ-
ence was not statistically significant.
The concentrations of PGE2 were highest in the
control specimens and lowest in the nasal polyps of
the CRS-AIA group (Fig. 1b). Comparison of the con-
centrations of PGE2 in the nasal polyps of the two pa-
tients groups (CRS-ATA and CRS-AIA) divided ac-
cording to the type of BA associated with CRS (ATA
Yoshimura T et al.
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Fig. 2 Corelation between the concentration of PGD2 and the number of tryptase-positive cels 
(a), PGE2 and the number of CD68-positive cels (b). Corelation analysis was performed using 
Spearman’ srank corelation coeficient (● :CRA-NA, ○ :CRS-ATA, △ :CRS-AIA).
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Fig. 3 Balance among the PGD2, PGE2, CysLTs concentrations in the nasal polyps. PGD2/PGE2 ratio (a), PGD2/CysLTs ratio 
(b) and PGE2/CysLTs ratio (c). Between-group comparisons were performed by Mann-Whitney’ sU-test with Bonferoni corec-
tion ( ＊ p＜0.05, ＊ ＊ p＜0.01).
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and AIA, respectively) revealed that the concentra-
tion of PGE2 was lower in the CRS-AIA group than in
the CRS-ATA group (P = 0.024).
The concentrations of CysLTs were significantly
higher in the nasal polyps of the CRS-AIA group than
in the control specimens (P = 0.037, Fig. 1c). The
same parameter tended to be higher in the CRS-AIA
group than in the CRS-ATA group, although this dif-
ference was not statistically significant.
EXPRESSION OF MAST CELL TRYPTASE AND
CD68 IN THE NASAL POLYPS
Next, the mast cells and monocyte macrophages in
the nasal polyps were counted by means of immuno-
histochemical staining and their counts were ana-
lyzed in relation to the levels of expression of the ara-
chidonic acid metabolites (Fig. 2). The results re-
vealed that the number of mast cell tryptase-positive
cells was strongly correlated with the concentrations
of PGD2 (r = 0.702, P < 0.001; Fig. 2a). According to
the analysis in each group, the number of mast cell
tryptase-positive cells was correlated with the concen-
trations of PGD2 in the CRS-NA group (P < 0.001) and
the CRS-ATA group (P = 0.029). The number of CD
68-positive cells was correlated with the concentra-
tions of PGE2 in the nasal polyps (r = 0.294, P = 0.048;
Fig. 2b). According to the analysis in each group, the
number of CD68-positive cells was correlated with
the concentrations of PGE2 in the CRS-NA group (P =
0.044).
COMPARISON OF THE ARACHIDONIC ACID ME-
TABOLITES
The PGD2PGE2 ratio, serving as an indicator of the
balance between PGD2 and PGE2, was compared
among the different groups (Fig. 3a). The PGD2
PGE2 ratio was found to be the highest in the CRS-
AIA group, followed by that in the CRS-ATA group,
PGD2PGE2 Ratio in Nasal Polyps
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Fig. 4 Corelations between the PGD2/PGE2 ratio and the number of EG2-positive cels (a) and 
the percentage of eosinophil in peripheral blood (b). Corelation analysis was performed using 
Spearman’ srank corelation coeficient (● :CRA-NA, ○ :CRS-ATA, △ :CRS-AIA).
a.
0 5 10 15
PGD2/PGE2 (ratio)
r ＝ 0.302 P ＝ 0.044
E
G
2 
po
si
tiv
e 
ce
lls
/o
ne
 fi
el
d 
(c
el
ls
)
180
160
140
120
100
80
60
40
20
0
b.
0 5 10 15
PGD2/PGE2 (ratio)
r ＝ 0.612 P ＝ 0.001
P
er
ip
he
ra
l b
lo
od
 e
os
in
op
hi
ls
 (
%
)
35
30
25
20
15
10
5
0
and lowest in the CRS-NA group. Furthermore, the
PGD2CysLTs ratio (serving as an indictor of the bal-
ance between PGD2 and the CysLTs) and the PGE2
CysLTs ratio (serving as an indicator of the balance
between PGE2 and the CysLTs) were also compared
among the different groups, as shown in Figure 3b,
3c, respectively. There was no significant difference
in the PGD2CysLTs ratio. On the other hand,
the PGE2CysLTs ratio was the highest in the CRS-
NA group followed by that in the CRS-ATA group,
and lowest in the CRS-AIA group.
COMPARISON OF THE PGD2PGE2 RATIO AND
EOSINOPHILS IN THE NASAL POLYPS
Figure 4a shows the data concerning the correlation
between the PGD2PGE2 ratio and the number of
EG2-positive cells in the nasal polyps. The PGD2
PGE2 ratio was positively correlated with the number
of EG2-positive cells in the nasal polyps (r = 0.302; P =
0.044). According to analysis in each group, this ratio
was not correlated with the number of EG2-positive
cells in the nasal polyps although a tendency was ob-
served. Figure 4b shows the data concerning the cor-
relation between the PGD2PGE2 ratio and the differ-
ential eosinophil count in the peripheral blood. The
PGD2PGE2 ratio was positively correlated with the
peripheral blood differential eosinophil count (r =
0.612; P = 0.001). According to analyses in each
group, this ratio was not correlated with the number
of EG2-positive cells in the peripheral blood though a
tendency was observed.
DISCUSSION
From the findings in this study, we provided evi-
dence, for the first time, of a significant elevation of
the concentration of PGD2 in the nasal polyps of pa-
tients with CRS complicated by ATA (CRS-ATA). Fur-
thermore, we found that the PGD2PGE2 ratio was
markedly elevated in the nasal polyps of patients with
CRS complicated by AIA (CRS-AIA). Previous studies
have reported a strong correlation between the sever-
ity of BA and the concentrations of PGD2.19,32,33 In
contrast, it is generally believed that CRS with BA is
associated with a poor prognosis. Some reports have
suggested that similar pathogenetic mechanisms
might be involved in BA and CRS in patients with
CRS complicated by BA.4-6,10 Based on these observa-
tions, we analyzed the PGD2 and PGE2 concentra-
tions in the nasal polyps of patients with intractable
CRS complicated by BA.
The CRS patients from whom the nasal polyp speci-
mens were collected were divided into three groups:
(1) CRS-NA (CRS patients without BA), (2) CRS-ATA
(CRS patients with complicating aspirin-tolerant (no
aspirin sensitivity) asthma) and (3) CRS-AIA (CRS pa-
tients with complicating aspirin-intolerant (aspirin-
sensitive) asthma). The PGD2 concentrations were
highest in the nasal polyps of the CRS-ATA group
(Fig. 1a). This result endorses the view that there
might be a close correlation between the pathophysi-
ology of BA and PGD2, and suggests that PGD2
might be involved in the intractable course of CRS.
Based on this finding, we checked the expression of
tryptase of mast cell origin in the nasal polyps by
means of immunohistochemical analysis. This analy-
sis revealed a positive correlation between the
tryptase-positive cell count and the nasal polyp PGD2
concentration (Fig. 2a). This finding suggested that
PGD2 production is elevated in nasal polyps showing
intense mast cell infiltration. The PGD2 concentration
tended to be lower in the polyps of the CRS-AIA
group than in those of the CRS-ATA group, although
this difference was not statistically significant (Fig. 1
a). In previous reports, the pathogenesis of AIA was
attributed to downregulation of cyclooxygenase
(COX)-2, and it was shown that COX-2 downregula-
Yoshimura T et al.
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tion leads to an increase in the production of CysLTs
and decrease in the production of PGE2.34-37 In the
present study also, significantly lower PGE2 concen-
trations (Fig. 1b) and significantly higher CysLTs
concentrations (Fig. 1c) were found in the polyps of
the CRS-AIA group. We may therefore estimate that
COX-2 downregulation is responsible for the reduc-
tion of the PGD2 concentrations in the nasal polyps of
patients with CRS-AIA. When the correlation of the
PGE2 with the number of infiltrating cells as deter-
mined by immunohistochemical analysis was exam-
ined, a positive correlation was noted between the
PGE2 concentration and the CD68-positive cell count
(Fig. 2b). On the basis of these results, we may esti-
mate that the PGE2 production is primarily under-
taken by macrophages.
It has recently been reported that the PGD2PGE2
balance is closely involved in various inflammatory
conditions.28,29,38 In the present study also, the
PGD2PGE2 ratio was in the order of CRS-AIA group
> CRS-ATA group > CRS-NA group (Fig. 3a). That is,
this ratio was higher in cases with intractable CRS
that was considered to be likely to be characterized
by repeated cycles of remission and relapse (e.g.,
CRA-AIA and CRS-ATA). Furthermore, a positive cor-
relation was noted between the PGD2PGE2 ratio and
the nasal polyp EG2-positive cell count (Fig. 4a) and
between the PGD2PGE2 ratio and the percentage of
eosinophils in the peripheral blood (Fig. 4b), suggest-
ing that the PGD2PGE2 ratio may serve as an indica-
tor of the severity of CRS, as is the case with tissue
and peripheral eosinophil counts. However, it is un-
clear why this ratio correlated with the percentage of
eosinophils in the peripheral blood. In previous re-
ports, PGD2 induced the rapid release of eosinophils
from bone marrow though PGE2 induced apoptosis in
developing eosinophils through inducible nitric oxide
synthase (NOS) and inhibited the responses of bone-
marrow myeloid progenitors to GM-CSF and of
eosinophil precursors to IL-5.39-41 We considered that
high PGD2 and low PGE2 levels might increase
eosinophils in the peripheral blood accordingly. In
this connection, Pierzchalska et al.42 reported a study
involving stimulation of fibroblasts (cultured after col-
lection from bronchial biopsy specimens) with IL-1β,
TNF-α or LPS and analysis of the expression of PGE2
and PGD2 in vitro, in which they demonstrated that
the PGE2PGD2 ratio was significantly lower in these
fibroblasts as compared with those in the fibroblasts
isolated from non-asthmatic patients. In contrast to
the design of their study, our study was designed to
quantify the expression of PGD2 and PGE2 through-
out all tissues containing cells capable of producing
them. Therefore, the data from this study may be
viewed as reflecting clinical cases more faithfully. Re-
garding the pathophysiology of CRS, Okano et al.30
analyzed the nasal polyp levels of PGD2 synthase
(PGDS) and PGE2 synthase (PGES) in patients with
CRS, based on the contention that an increase in
PGD2 and decrease in PGE2 can aggravate
eosinophil-induced airway inflammation. Our study
differs from theirs in that our study involved the
quantification of arachidonic acid metabolites in the
nasal polyps by EIA instead of analysis of the respec-
tive syntheses. Furthermore, by dividing CRS compli-
cated by asthma into two types (a type with aspirin
sensitivity and a type without aspirin sensitivity), the
present study demonstrated a closer correlation of
the PGD2PGE2 ratio with CRS-AIA (CRS compli-
cated by asthma with aspirin sensitivity) than with
CRS-ATA. Furthermore, both the PGD2CysLTs ratio
(Fig. 3b) and the PGE2CysLTs ratio (Fig. 3c) were
lower in the CRS-AIA group than in the CRS-ATA
group. These results seem to be attributable to the
greater downregulation of COX-2 in these cases, as
described above.
In the analysis of the association with predisposi-
tion to allergy, no significant correlation was noted
between the PGD2PGE2 ratio and the serum total
IgE level (data not shown). These results suggest
that the PGD2PGE2 ratio may be independent of
atopic status.
Some investigators reported that paranasal sinus
CT scans tend to reveal more severe lesions in cases
of CRS with intense eosinophil infiltration (e.g., cases
of CRS-ATA and CRS-AIA).43 If this previous finding
is taken into consideration with the results of the pre-
sent study, it seems likely that the PGD2PGE2 ratio
correlates positively with the radiological severity of
CRS. In the previous report, a significant positive cor-
relation was noted between the haemopoietic-type
PGDS (h-PGDS) levels and the radiological severity
of sinusitis, while a significant inverse correlation was
noted between the microsomal PGES-1 (m-PGES-1)
levels and the severity.30 However, the PGD2PGE2
ratio were not correlated with radiological severity of
sinusitis in this study (P = 0.189; data not shown).
One possible reason for this finding is that in cases
with intense eosinophil infiltration (e.g., CRS-AIA
group and CRS-ATA group), lesions are often con-
fined to the ethmoid sinus or the surrounding area
and the CT score is not always high.
In conclusion, the concentrations of the PGD2 were
significantly higher in the polyps obtained from pa-
tients with CRS-ATA as compared with those in the
control specimens. The concentrations of PGE2 were
highest in the control specimens, followed by those
in the CRS-ATA group, and lowest in the CRS-AIA
group. The PGD2PGE2 ratio was highest in the CRS-
AIA group, followed by that in the CRS-ATA group,
and lowest in the CRS-NA group. These findings sug-
gest that the PGD2PGE2 ratio may be an indicator of
the severity of CRS as one of the alternatives to the
eosinophilic infiltration. Clinically, CRS complicated
by AIA is known to be characterized by repeated cy-
cles of remission and relapse and to be highly intrac-
PGD2PGE2 Ratio in Nasal Polyps
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table. Because such cases had the highest nasal
polyp PGD2PGE2 ratio in the present study, we may
say that the PGD2PGE2 ratio reflects the intractable
nature of CRS very well. Treatment of intractable CRS
may be possible if the increase of PGD2 and decrease
of PGE2 in such cases can be controlled.
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